Full-Time

Analyst – 2026 Bachelor's graduates

European Competition practice

Posted on 9/16/2025

Charles River Associates (CRA)

Charles River Associates (CRA)

1,001-5,000 employees

Global consulting delivering economic, litigation analysis

No salary listed

London, UK

Hybrid

Hybrid role; 3–4 days per week in-office, with occasional remote options during holidays.

Category
Consulting (1)
Required Skills
Python
R
Stata
Data Analysis
Requirements
  • An undergraduate qualification in economics.
  • Minimal travel is required.
Responsibilities
  • Identify potential issues and conduct analyses that can be used to illustrate economic arguments;
  • Assemble compelling evidence from data and research that support our expert opinions and business recommendations;
  • Program, build models, and/or perform regression analyses in statistical analysis programs (such as Stata, Python, R), including large data projects requiring use of cloud computing;
  • Assist in the development and presentation of client deliverables, including expert reports and white papers summarising opinions, conclusions, and recommendations using financial, market, industry or client-proprietary data;
  • Interact with clients and communicate complicated economic concepts and arguments to non-experts in an understandable, accessible manner;
  • Ensure the integrity and accuracy of analyses and opinions;
  • Participate in practice-building activities (training, recruiting, publication, expertise sharing, etc.).
Desired Qualifications
  • An undergraduate qualification (Bachelors/BA) in economics from well-regarded institutions, graduating between December 2025 and August 2026, with consideration for pursuing postgraduate study after 1-2 years of employment;
  • Strong foundation in microeconomics, with a specialism in industrial economics preferred;
  • High degree of numeracy and comfort with data manipulation; familiarity with econometric techniques desirable;
  • Curious and analytical thinkers who bring creative approaches to non-standard problems;
  • Effective oral and written communication skills;
  • Eagerness to learn new skills and programming languages;
  • Demonstrated high level of initiative and leadership;
  • Strong teamwork and collaboration capabilities;
  • Excellent time management and task prioritisation skills;
  • Clear and demonstrated interest in consulting through coursework, work experience, activities, or attendance at CRA recruiting events.
Charles River Associates (CRA)

Charles River Associates (CRA)

View

CRA is a global consulting firm that offers specialized services in litigation, regulatory, financial, and management consulting. It uses economic and financial analysis, modeling, and expert testimony to support clients in disputes, regulatory matters, and strategic decisions. The firm differentiates itself through rigorous quantitative analysis, industry expertise, and a worldwide network that delivers tailored, objective insights. Its goal is to help clients achieve favorable outcomes by providing precise analyses, clear testimony, and practical recommendations.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

City of Brussels, Belgium

Founded

1978

Simplify Jobs

Simplify's Take

What believers are saying

  • Record Q1 2026 revenue of $201M with 10.5% growth; eight practices expanding.
  • Hitesh Makhija hire strengthens antitrust capabilities amid intensifying M&A and regulatory activity.
  • Stock trades 55% below fair value at $139; analysts maintain $252 price target.

What critics are saying

  • Q1 earnings miss 15% triggers 12% stock drop; growth slows to 3.2% annually.
  • Cyclical M&A and regulatory deal flow collapse eliminates core revenue drivers entirely.
  • Talent poaching drains expertise; Makhija's prior departure signals retention vulnerability in high-margin practices.

What makes Charles River Associates (CRA) unique

  • Founded by Harvard and MIT professors; rigorous analytical heritage differentiates from competitors.
  • Serves 88% of Fortune 100 and 98% of Am Law 100 with deep client relationships.
  • Specialized expertise in antitrust, IP, transfer pricing, and forensic finance commands premium fees.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Flexible Work Hours

Remote Work Options

Professional Development Budget

Company News

Business Wire
Apr 2nd, 2026
CRA appoints Christine Detrick as Lead Independent Director as William Concannon retires after 26 years

Charles River Associates has announced that Director Christine Detrick will become Lead Independent Director, effective 16th July 2026, following the planned retirement of current Lead Independent Director William Concannon. Concannon's retirement will take effect at CRA's 2026 Annual Meeting of Shareholders. Concannon has served on CRA's board since 2000 and as Lead Director since 2020. He informed the board of his decision to retire to spend more time with family. Detrick has been a board member since 2020 and currently chairs the Nominating and Corporate Governance Committee. CRA is a global consulting firm specialising in economic, financial and management consulting services, headquartered in Boston with offices worldwide.

The Pharma Letter
Mar 17th, 2026
Invest in European pharma to reap dividends, report says.

Invest in European pharma to reap dividends, report says. 17 March 2026 The European Federation of Pharmaceutical Industries and Associations (EFPIA) has highlighted the findings from a report by consultants Charles River Associates (Nasdaq: CRAI) that the trade group had commissioned. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK 16 March 2026 9 March 2026 16 February 2026 Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news 17 March 2026 Company spotlight. A private biotechnology company developing synthetic macrocyclic peptide therapeutics designed to target historically "undruggable" proteins. Unnatural Products focuses on bridging the gap between small molecules and biologics through orally available, cell-permeable macrocycles. More features in pharmaceutical. 17 March 2026

Yahoo Finance
Mar 9th, 2026
CRA International raises 2026 revenue outlook to $805M, maintains $0.57 dividend

CRA International has raised its 2026 revenue guidance to $785 million to $805 million in constant currency, signalling expectations for higher consulting demand. The company reported fourth-quarter 2025 revenue of $196.96 million and full-year 2025 revenue of $751.58 million, with net income of $54.78 million. The firm declared a quarterly dividend of $0.57 per share, payable on 20 March 2026. This marks continued cash returns to shareholders despite net debt of approximately $100.6 million. CRA's investment narrative remains tied to consulting demand driven by global mergers and acquisitions and regulatory activity. The key risk is demand cyclicality, particularly if dealmaking or enforcement activity slows sharply. Community fair value estimates for the stock range from $252 to $333 per share.

Business Wire
Mar 4th, 2026
CRA adds renowned digital economy expert Dr Steven Tadelis to strengthen antitrust testifying capabilities

Charles River Associates has appointed Dr Steven Tadelis, a professor at UC Berkeley's Haas School of Business, as a senior consultant to its Antitrust & Competition Economics Practice. Dr Tadelis specialises in e-commerce and internet economics, with research covering digital advertising effectiveness, online marketplace reputation systems and algorithmic pricing. Dr Tadelis has provided expert economic testimony in major US and Canadian litigation cases involving digital markets and participated in Federal Trade Commission hearings. He previously held senior roles at eBay Research Labs and Amazon, serving as vice president of economics and market design. The appointment strengthens CRA's testifying capabilities in antitrust and consumer protection cases involving digital platforms and internet economics.

Yahoo Finance
Feb 27th, 2026
Charles River Associates hits record annual revenue with Q4 at $197M, beats consensus despite EPS miss

Charles River Associates reported fourth-quarter revenue of $196.96 million, beating consensus estimates of $190.54 million, though earnings per share of $2.06 fell slightly short of the $2.07 consensus. The company achieved its eighth consecutive year of record annual revenue. Revenue grew 11.6% year-over-year in the fourth quarter, driven by double-digit growth in four practices: Antitrust & Competition Economics, Energy, Forensic Services, and Labor & Employment. Life Sciences and Risk, Investigations & Analytics also expanded. Geographically, North American operations increased 9.4% whilst international operations grew 21.9%. CEO Paul Maleh said strong top-line growth drove record profitability, with net income, earnings per diluted share and EBITDA each reaching new annual highs.

INACTIVE